CD274 and colorectal carcinoma: Therefore, eliciting an enhanced response to anti-PD-1/PD-L1 mAbs in patients with pMMR/MSI-L CRC may require combined therapeutics with other anti-immunosuppressive, antiangiogenic or anti-immune checkpoint bioagents (42, 105).